Combination ibandronate and radiotherapy for the treatment of bone metastases: Clinical evaluation and radiologic assessment

doi:10.1016/j.ijrobp.2006.08.022

Title: Combination ibandronate and radiotherapy for the treatment of bone metastases: Clinical evaluation and radiologic assessment

Full Record
Similar

Abstract

Purpose: Ibandronate is a single-nitrogen, noncyclic bisphosphonate with proven efficacy for reducing metastatic bone pain. In this study, we assessed the palliative effects of combined ibandronate and radiotherapy. Methods and Materials: Forty-five patients with bone metastases from various solid tumors received external-beam radiotherapy, 30-40 Gy over 3-4.5, weeks combined with 10 cycles of monthly intravenous ibandronate, 6 mg. Results: After combined therapy, mean bone pain scores (graded from 0 to 10) were reduced from 6.3 at baseline to 0.8 after 3 months, with further reductions at later time points (all p < 0.001). Opioid use decreased from 84% of patients at baseline (38/45) to 24% (11/45) at 3 months, with further subsequent reductions (all p < 0.001). Mean performance status and functioning scores also significantly improved. Bone density (assessed by computed tomography scan) increased by 20% vs. baseline at 3 months, 46% at 6 months, and 73% at 10 months (all p < 0.001). Lesion improvement was also demonstrated by magnetic resonance imaging. Treatment was well tolerated with no renal toxicity. Conclusions: In this pilot study, combined radiotherapy and ibandronate provided substantial bone pain relief and increased bone density. Computed tomography-based or magnetic resonance imaging-based evaluations offer objective methods formore » assessing therapeutic outcomes.« less

Authors:

Vassiliou, Vassilios ^[1]; Kalogeropoulou, Christine ^[2]; Christopoulos, Christos ^[1]; Solomou, Ekaterini ^[2]; Leotsinides, Michael ^[3]; Kardamakis, Dimitrios ^[4]

Department of Radiotherapy, University of Patras Medical School, Patras (Greece)
Department of Radiology, University of Patras Medical School, Patras (Greece)
Laboratory of Public Health, University of Patras Medical School, Patras (Greece)
Department of Radiotherapy, University of Patras Medical School, Patras (Greece). E-mail: kardim@med.upatras.gr

Publication Date:: Mon Jan 01 00:00:00 EST 2007

OSTI Identifier:: 20850324

Resource Type:: Journal Article

Resource Relation:: Journal Name: International Journal of Radiation Oncology, Biology and Physics; Journal Volume: 67; Journal Issue: 1; Other Information: DOI: 10.1016/j.ijrobp.2006.08.022; PII: S0360-3016(06)02755-6; Copyright (c) 2007 Elsevier Science B.V., Amsterdam, Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA)

Country of Publication:: United States

Language:: English

Subject:: 62 RADIOLOGY AND NUCLEAR MEDICINE; COMBINED THERAPY; COMPUTERIZED TOMOGRAPHY; EVALUATION; METASTASES; NEOPLASMS; NMR IMAGING; PAIN; PATIENTS; PERFORMANCE; RADIOTHERAPY; SKELETON; TOXICITY

Citation Formats


                    Vassiliou, Vassilios, Kalogeropoulou, Christine, Christopoulos, Christos, Solomou, Ekaterini, Leotsinides, Michael, and Kardamakis, Dimitrios. Combination ibandronate and radiotherapy for the treatment of bone metastases: Clinical evaluation and radiologic assessment.  United States: N. p., 2007. 
        Web.  doi:10.1016/j.ijrobp.2006.08.022.

Copy to clipboard


                    Vassiliou, Vassilios, Kalogeropoulou, Christine, Christopoulos, Christos, Solomou, Ekaterini, Leotsinides, Michael, & Kardamakis, Dimitrios. Combination ibandronate and radiotherapy for the treatment of bone metastases: Clinical evaluation and radiologic assessment.  United States.  doi:10.1016/j.ijrobp.2006.08.022.

Copy to clipboard


                    Vassiliou, Vassilios, Kalogeropoulou, Christine, Christopoulos, Christos, Solomou, Ekaterini, Leotsinides, Michael, and Kardamakis, Dimitrios. Mon .  
        "Combination ibandronate and radiotherapy for the treatment of bone metastases: Clinical evaluation and radiologic assessment".  United States.  
        doi:10.1016/j.ijrobp.2006.08.022.

Copy to clipboard


                    
@article{osti_20850324,

  title        = {Combination ibandronate and radiotherapy for the treatment of bone metastases: Clinical evaluation and radiologic assessment},

  author       = {Vassiliou, Vassilios and Kalogeropoulou, Christine and Christopoulos, Christos and Solomou, Ekaterini and Leotsinides, Michael and Kardamakis, Dimitrios},

  abstractNote = {Purpose: Ibandronate is a single-nitrogen, noncyclic bisphosphonate with proven efficacy for reducing metastatic bone pain. In this study, we assessed the palliative effects of combined ibandronate and radiotherapy. Methods and Materials: Forty-five patients with bone metastases from various solid tumors received external-beam radiotherapy, 30-40 Gy over 3-4.5, weeks combined with 10 cycles of monthly intravenous ibandronate, 6 mg. Results: After combined therapy, mean bone pain scores (graded from 0 to 10) were reduced from 6.3 at baseline to 0.8 after 3 months, with further reductions at later time points (all p < 0.001). Opioid use decreased from 84% of patients at baseline (38/45) to 24% (11/45) at 3 months, with further subsequent reductions (all p < 0.001). Mean performance status and functioning scores also significantly improved. Bone density (assessed by computed tomography scan) increased by 20% vs. baseline at 3 months, 46% at 6 months, and 73% at 10 months (all p < 0.001). Lesion improvement was also demonstrated by magnetic resonance imaging. Treatment was well tolerated with no renal toxicity. Conclusions: In this pilot study, combined radiotherapy and ibandronate provided substantial bone pain relief and increased bone density. Computed tomography-based or magnetic resonance imaging-based evaluations offer objective methods for assessing therapeutic outcomes.},

  doi          = {10.1016/j.ijrobp.2006.08.022},

  journal      = {International Journal of Radiation Oncology, Biology and Physics},

  number       = 1,

  volume       = 67,

  place        = {United States},

  year         = {Mon Jan 01 00:00:00 EST 2007},

  month        = {Mon Jan 01 00:00:00 EST 2007}

}

Copy to clipboard

Journal Article:

DOI: 10.1016/j.ijrobp.2006.08.022

Other availability

Find in Google Scholar

Search WorldCat to find libraries that may hold this journal

Save / Share:

Export Metadata

Save to My Library

Update of the International Consensus on Palliative Radiotherapy Endpoints for Future Clinical Trials in Bone Metastases

Chow, Edward, E-mail: Edward.Chow@sunnybrook.ca ; Hoskin, Peter ; Mitera, Gunita ; ... - International Journal of Radiation Oncology, Biology and Physics

Purpose: To update the international consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases by surveying international experts regarding previous uncertainties within the 2002 consensus, changes that may be necessary based on practice pattern changes and research findings since that time. Methods and Materials: A two-phase survey was used to determine revisions and new additions to the 2002 consensus. A total of 49 experts from the American Society for Radiation Oncology, the European Society for Therapeutic Radiology and Oncology, the Faculty of Radiation Oncology of the Royal Australian and New Zealand College of Radiologists, and the Canadianmore »« less
DOI: 10.1016/J.IJROBP.2011.02.008
Iodine-131-labeled diphosphonates for palliative treatment of bone metastases: II. Preliminary clinical results with iodine-131 BDP3

Eisenhut, M. ; Berberich, R. ; Kimmig, B. ; ... - J. Nucl. Med.; (United States)

The kinetics, dosimetry, and response of iodine-131 alpha-amino-(4-hydroxybenzylidene)-diphosphonate ((/sup 131/I)BDP3) treatment were investigated with patients who had pain symptoms from bone metastases of various primary carcinoma. The blood clearance of (/sup 131/I)BDP3 was rapid. More than 90% disappeared from the blood pool at 2 hr after injection. The excretion of the activity occurred solely through the kidneys and mean total-body retention at 48 hr was 48.6%. The urinary activity showed a metabolite which must be formed by an in vivo cleavage reaction of a phosphorus-carbon bond. The uptake of in vivo cleaved (/sup 131/I)iodide in the unblocked thyroid was approximatelymore »« less
Prospective multicenter study of combined treatment with chemotherapy and radiotherapy in breast cancer women with the rare clinical scenario of ipsilateral supraclavicular node recurrence without distant metastases

Pergolizzi, Stefano ; Adamo, Vincenzo ; Russi, Elvio ; ... - International Journal of Radiation Oncology, Biology and Physics

Purpose: To evaluate the role of chemotherapy combined with curative radiotherapy in breast cancer patients who presented with recurrent ipsilateral supraclavicular lymph node metastases (ISLM) without 'nonregional disease,' we designed an observational study performed prospectively. Patients and Methods: Forty-four consecutive patients with ISLM from breast cancer as part of recurrent regional disease without distant metastases were included in this study. All patients received chemotherapy with doxorubicin-based schema or paclitaxel for six courses and curative radiotherapy (60 Gy/30 fractions of 2 Gy/5 days a week). An 'involved field' radiation was delivered during the interval between the third and fourth chemotherapy course;more »« less
DOI: 10.1016/J.IJROBP.2005.1
Hypofractionated conformal stereotactic radiotherapy alone or in combination with whole-brain radiotherapy in patients with cerebral metastases

Lindvall, Peter ; Bergstroem, Per ; Loefroth, Per-Olov ; ... - International Journal of Radiation Oncology, Biology and Physics

Purpose: The aim was to evaluate treatment of cerebral metastases with hypofractionated conformal stereotactic radiotherapy (HCSRT) or whole-brain radiotherapy (WBRT) in combination with a stereotactic boost. Methods and Materials: Forty-seven patients were treated with HCSRT and 14 patients with WBRT in combination with a stereotactic boost. Radiation doses were 40 Gy (5 fractions) in HCSRT or 30 Gy (WBRT) combined with a mean dose of 17 Gy stereotactically (1-3 fractions). Results: The median survival time in the HCSRT as well as the WBRT group was 5.0 months, and 87% died of extracranial disease. Radiologic follow-up (mean, 3.7 months after treatment)more »« less
DOI: 10.1016/j.ijrobp.2004.08.027
Clinical relevance of radiologic examination of the skeleton and bone density measurements in osteoporosis of old age

Kuester, W. ; Seidl, G. ; Linkesch, W. ; ... - Skelet. Radiol.; (United States)

For the diagnosis of primary osteoporosis, various semiquantitative radiologic methods were compared in 149 unselected patients, aged over 50 years. Crush fracture syndrome (CFS), lumbar spine index (LSI), and Singh Index (SI) were assessed by three radiologists and after reevaluation, the intra- and interobserver errors were calculated. The reliability of the subjective grading was improved by joint and repeated reading of the radiographs. Additionally, the peripheral trabecular bone content was measured by photon absorption densitometry (PAD). To test the value of the various semiquantitative methods. LSI, Si, and PAD have been compared with sex-matching before and after separation into agemore »« less